Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Venture&Growth
SpliceBio
SpliceBio is a Spanish therapeutics company addressing the key limitations of current gene therapy. It harnesses its proprietary Protein Splicing platform to develop next-generation gene therapies, based on engineered inteins pioneered at the Muir Lab at Princeton University. The company

Venture&Growth
Nyxoah
Belgian Healthtech company focused on the treatment of sleep apnea.

Venture&Growth
Noema Pharma
Swiss Therapeutics company developing therapies to treat severe neurological disorders.
